Discuss the role of Opioid free anaesthesia in present day practice of anaesthesia. List its potential benefits and limitations in perioperative pain management. (Jan 2025) Recent Advances in anesthesia for intrauterine fetal Surgery. (Jan 2025) Use of ultrasound for airway assessment and management. (Jan 2025) What is hospital acquired infections? Describe the causes, prevention and management of ventilator associated pneumonia. (Sept 2025) Give answer for this question from standard anaesthesia text book on exam pov of view and how to write

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here are all four questions answered in full exam-style format, based on Miller's Anesthesia (10e), Morgan & Mikhail's Clinical Anesthesiology (7e), Barash's Clinical Anesthesia (9e), and Fishman's Pulmonary Diseases:

HOW TO WRITE ANAESTHESIA EXAM ANSWERS - GENERAL TIPS

Before the answers, understand the exam structure:
  • 10-mark question: Introduction (2-3 lines) + Body with headings (7-8 marks) + Conclusion (1-2 lines)
  • Always use headings, subheadings, and bullet points - examiners scan, not read
  • Start every answer with a definition or brief introduction
  • Use tables where comparison or classification is asked
  • End with a brief conclusion showing clinical perspective
  • For "discuss" questions, cover: definition, mechanism, clinical use, benefits, limitations, complications


QUESTION 1: Opioid Free Anaesthesia (OFA) - Role, Benefits and Limitations in Perioperative Pain Management


INTRODUCTION

Opioid Free Anaesthesia (OFA) refers to an anaesthetic technique in which opioids are completely avoided intraoperatively, relying instead on a combination of non-opioid analgesics, regional techniques, and adjuvant drugs to achieve adequate analgesia and obtund surgical stress responses. This concept has gained prominence in the context of the global opioid epidemic and increasing concerns about opioid-related adverse effects including postoperative delirium.

BACKGROUND AND RATIONALE

The perioperative routine use of opioids is being reconsidered due to:
  1. The opioid crisis - widespread prescription opioid abuse
  2. Increased awareness of postoperative delirium in ICU/elderly patients
  3. Opioid-induced hyperalgesia (OIH)
  4. Postoperative nausea and vomiting (PONV)
  5. Respiratory depression
  6. Immunosuppressive effects of opioids
  7. Opioid tolerance and dependence
(Miller's Anesthesia 10e, Chapter 47)

PHARMACOLOGICAL COMPONENTS OF OFA

OFA utilises a multimodal pharmacological approach:
CategoryDrugs Used
Alpha-2 agonistsDexmedetomidine, Clonidine
NMDA antagonistsKetamine (S-ketamine), Magnesium sulphate
Local anaesthetic infusionsSystemic Lidocaine (IV infusion)
NSAIDs / COX-2 inhibitorsKetorolac, Parecoxib, Celecoxib
Alpha-2-delta ligandsGabapentin, Pregabalin
GlucocorticoidsDexamethasone
ParacetamolRegular IV/oral acetaminophen
Regional anaesthesiaEpidural, TAP block, PEC block, peripheral nerve blocks
Volatile anaestheticsHigh-dose inhalational agents
Beta-blockersEsmolol (to suppress surgical stress response)

MECHANISMS OF NON-OPIOID ANALGESIA

  • Dexmedetomidine: Acts on presynaptic alpha-2 receptors in locus coeruleus, reduces norepinephrine release, provides sedation, analgesia, and anxiolysis
  • Ketamine: NMDA receptor antagonism prevents central sensitisation and wind-up; reduces opioid requirements by 30-50%
  • IV Lidocaine: Blocks sodium channels, reduces cytokine release, anti-hyperalgesic
  • Gabapentin/Pregabalin: Blocks voltage-gated calcium channels, reduces presynaptic glutamate release
  • Dexamethasone: Anti-inflammatory, reduces prostaglandin synthesis, prolongs regional block duration

POTENTIAL BENEFITS OF OFA

1. Reduction of PONV

  • Studies show OFA reduces postoperative nausea and vomiting, particularly in bariatric surgery, beyond triple antiemetic prophylaxis (Morgan & Mikhail 7e)

2. Avoidance of Respiratory Depression

  • Particularly important in obese patients, obstructive sleep apnoea, and paediatric tonsillectomy

3. Prevention of Opioid-Induced Hyperalgesia (OIH)

  • High-dose intraoperative opioids activate anti-nociceptive pathways paradoxically, worsening postoperative pain

4. Reduced Postoperative Delirium

  • Relevant in elderly ICU patients where opioids are a recognised modifiable risk factor

5. Better Surgical Conditions

  • Reduced ileus, earlier return of bowel function (especially important in colorectal/bariatric surgery)
  • Faster extubation and discharge (key in ERAS protocols)

6. Reduced Risk of Opioid Dependence

  • Especially relevant in opioid-naive patients and those with substance use disorders

7. Improved Immune Function

  • Opioids suppress NK cell activity; avoiding them may preserve perioperative immune function

8. Benefit in Chronic Pain Patients

  • Avoids exacerbating existing opioid tolerance

LIMITATIONS OF OFA

1. Haemodynamic Instability

  • Large proof-of-concept studies have been terminated prematurely due to high incidences of hypoxia and bradycardia
  • Some studies showed increased demand for vasopressors, hypotension, and bradycardia (Miller's Anesthesia 10e)
  • Dexmedetomidine causes bradycardia and hypotension

2. Postoperative Sedation and Falls

  • Residual effects of dexmedetomidine can cause sedation extending into the postoperative period

3. Inadequate Analgesia for Major Surgery

  • For highly nociceptive procedures (thoracotomy, open abdominal surgery), complete opioid avoidance may be insufficient

4. Dependence on Regional Anaesthesia

  • OFA works best when combined with regional techniques, which carry their own risks (block failure, nerve injury, haematoma)

5. Drug Interactions and Side Effects of Adjuvants

  • Ketamine: dysphoria, hallucinations, raised ICP
  • NSAIDs: renal impairment, GI bleeding, platelet dysfunction
  • Pregabalin: dizziness, sedation

6. Evidence Gaps

  • Most evidence comes from specific populations (bariatric, gynaecology); evidence for major cardiac/thoracic surgery is limited
  • No large RCTs conclusively demonstrating superiority over opioid-sparing analgesia

7. Not a Universal Solution

  • OFA is not a panacea; opioid-sparing analgesia (minimising rather than completely eliminating opioids) may be more practical and safer in most patients (Miller's Anesthesia 10e, Chapter 47)

OFA vs OPIOID-SPARING ANALGESIA

FeatureOFAOpioid-Sparing
Opioid doseZeroReduced
Evidence baseLimitedStrong
PONV benefitMaximumSignificant
Haemodynamic stabilityCompromisedBetter
ApplicabilitySelected casesUniversal
ERAS compatibilityHighHigh

CURRENT STANDING AND CONCLUSION

OFA represents an intellectually appealing concept but is not yet the universal solution to perioperative pain management. The multimodal pharmacological approach underlying OFA has undeniable benefits in specific populations - obese patients, chronic pain patients, paediatric tonsillectomy, and opioid-dependent patients. However, the anesthesiologist must balance these benefits against real risks of haemodynamic instability and inadequate analgesia. In current practice, a tailored opioid-sparing multimodal approach rather than strict OFA is the recommended standard for most patients, with OFA reserved for carefully selected cases. (Miller's Anesthesia 10e, Barash Clinical Anesthesia 9e)


QUESTION 2: Recent Advances in Anaesthesia for Intrauterine Fetal Surgery


INTRODUCTION

Intrauterine fetal surgery encompasses a spectrum of interventions performed before birth to correct anatomical malformations that would otherwise lead to irreversible fetal harm or demise. Advances in prenatal diagnosis, fetal imaging, minimally invasive surgical techniques, and anaesthetic management have collectively expanded the scope and safety of fetal interventions. The anaesthesiologist plays a pivotal role addressing the unique dual-patient challenge - the pregnant mother and the fetus. (Miller's Anesthesia 10e, Chapter 59)

CLASSIFICATION OF FETAL SURGICAL PROCEDURES

Fetal surgery is classified into three types:

1. Minimally Invasive Procedures

  • FIGS-IT: Fetal Image-Guided Surgery for Intervention or Therapy - ultrasound-guided percutaneous needle-based interventions
  • Fetoscopic surgery: Small endoscopic instruments inserted percutaneously under direct camera + real-time ultrasound guidance
  • Reduced risk of preterm labour compared to open procedures

2. Open Fetal Surgery

  • Requires maternal laparotomy and hysterotomy
  • Highest level of anaesthetic requirement
  • Associated with significant maternal morbidity

3. Intrapartum Procedures (EXIT Procedures)

  • Ex-Utero Intrapartum Treatment
  • Uteroplacental circulation maintained while fetal airway is secured or lesion corrected at delivery

CONDITIONS AMENABLE TO FETAL SURGERY

ConditionProcedureEvidence
Twin-to-Twin Transfusion Syndrome (TTTS)Fetoscopic laser photocoagulation of placental vesselsLevel I RCT evidence
Myelomeningocele (spina bifida)Open or fetoscopic neural tube repairMOMS Trial: improved neurological outcomes
Congenital Diaphragmatic Hernia (CDH)Fetal Tracheal Balloon Occlusion (FETO)TOTAL trial
Lower Urinary Tract Obstruction (LUTO)Vesico-amniotic shunt placementPLUTO trial
Sacrococcygeal Teratoma (SCT)Debulking for high-output cardiac failureCase series
Congenital Pulmonary Airway Malformations (CPAM)Thoraco-amniotic shuntSelected cases
Obstructive uropathyVesico-amniotic shuntSelected cases

ANAESTHETIC CONSIDERATIONS

A. Maternal Anaesthesia

For Open Fetal Surgery:
  • General anaesthesia is required
  • High-dose volatile agents (desflurane/sevoflurane 1.5-2 MAC) provide:
    • Adequate maternal anaesthesia
    • Uterine relaxation (tocolysis)
    • Transplacental fetal anaesthesia
  • IV supplementation with desflurane reduces fetal cardiac dysfunction
  • Supplemental IV agents: propofol, remifentanil
  • Neuraxial anaesthesia (epidural) for postoperative pain management
For Minimally Invasive / Fetoscopic Procedures:
  • Local infiltration with sedation (IV fentanyl/midazolam), OR
  • Neuraxial anaesthesia (spinal/epidural) preferred
  • Avoids need for uterine relaxation agents in most cases

B. Fetal Anaesthesia and Analgesia

A landmark question in fetal surgery is whether the fetus perceives pain. Evidence suggests:
  • Nociceptive pathways and cortical connections are present by 24-28 weeks
  • Fetal stress responses (hormonal and haemodynamic) to noxious stimuli are well-documented
  • Direct fetal opioid analgesia has been shown to attenuate fetal hormonal and haemodynamic stress responses (Sabiston Surgery 14e)
Routes of fetal drug administration:
  • Transplacental (via maternal administration - volatile agents, opioids)
  • Intramuscular injection into the fetus (for fetoscopic procedures) - typically fentanyl + atropine + vecuronium
  • Intra-umbilical vein injection
Standard fetal IM cocktail:
  • Fentanyl 10-20 mcg/kg IM
  • Atropine 20 mcg/kg IM (prevent vagally mediated bradycardia)
  • Vecuronium/pancuronium (immobilisation)

C. Uterine Relaxation (Tocolysis)

Essential for open fetal surgery to prevent preterm labour:
  • Volatile anaesthetics at high doses (primary method for open surgery)
  • IV nitroglycerin (rapid but short-acting)
  • Magnesium sulphate (perioperative tocolysis)
  • Nifedipine / Indomethacin (postoperative tocolysis)

D. Fetal Monitoring

  • Continuous fetal echocardiography/fetal heart rate monitoring intraoperatively
  • Umbilical artery Doppler for flow abnormalities
  • Pulse oximetry (limited, on exteriorised fetal limb in open surgery)
  • Fetal scalp electrode (when applicable)

RECENT ADVANCES

1. Fetoscopic MMC Repair

  • Minimally invasive fetoscopic repair of myelomeningocele now performed via 3-port technique
  • Reduces maternal morbidity compared to open surgery
  • Requires combined spinal-epidural (CSE) with sedation

2. FETO for CDH (TOTAL Trial)

  • Fetoscopic balloon tracheal occlusion under local/neuraxial anaesthesia
  • Balloon placed between 27-30 weeks, removed at 34 weeks or before delivery
  • Improves survival in severe isolated left CDH (liver-up, o/e LHR < 25%)

3. EXIT Procedure Refinements

  • Airway secured on placental bypass before clamping cord
  • Anaesthesia: high-dose volatile + epidural; uterus kept relaxed
  • Used for giant neck masses, thoracic lesions, CPAM, laryngeal atresia

4. Fetal Cardiac Interventions

  • Aortic/pulmonary valvuloplasty by percutaneous needle under maternal sedation + local anaesthesia + direct fetal IM injection
  • Success rates of 60-70% for technical procedure

5. Neurodevelopmental Safety Concerns

  • FDA 2016 warning: anaesthetics may affect developing fetal brain (< 36 months)
  • Current evidence from human RCTs (GAS trial, PANDA trial) suggests single, short exposure poses minimal risk
  • Ongoing research into minimum effective dose of volatile anaesthetics

6. Three-Level Fetal Therapy Centres

  • Level I: low-risk interventions, no maternal ICU needed
  • Level II: preterm/maternal ICU capable
  • Level III: all open procedures, all complications manageable

COMPLICATIONS AND MANAGEMENT

ComplicationManagement
Fetal bradycardiaAtropine IM/IV into fetus; adjust volatile concentration; IV ephedrine
Preterm premature rupture of membranes (PPROM)Most common complication; conservative management or delivery
Preterm labourTocolysis (magnesium, nifedipine)
Maternal haemorrhageBlood products, uterotonics; avoid in open procedures until fetus delivered
Mirror syndromeDelivery; resembles severe preeclampsia
Umbilical cord accidentsEmergency delivery or endoscopic cord manipulation

CONCLUSION

The anaesthetic management of fetal surgery represents one of the most complex fields in anaesthesia, requiring expertise in obstetric, paediatric, and critical care anaesthesia simultaneously. The trend toward minimally invasive fetoscopic approaches under regional anaesthesia, combined with advances in fetal monitoring and understanding of fetal pain perception, has substantially improved outcomes. A dedicated multidisciplinary team at a specialised fetal therapy centre remains the cornerstone of safe fetal surgical practice. (Miller's Anesthesia 10e, Chapter 59)


QUESTION 3: Use of Ultrasound for Airway Assessment and Management


INTRODUCTION

Point-of-care ultrasound (POCUS) has emerged as a non-invasive, real-time imaging modality for airway assessment and management. Unlike traditional clinical airway evaluation methods (Mallampati, thyromental distance, neck circumference), ultrasound provides dynamic, objective anatomical information at the bedside without radiation. It has applications from pre-operative airway planning to emergency airway rescue. (Morgan & Mikhail Clinical Anesthesiology 7e; Miller's Anesthesia 10e)

ULTRASOUND ANATOMY OF THE AIRWAY

Key structures identified on airway ultrasound:
  • Thyroid cartilage - echogenic, inverted V-shaped, anterior
  • Cricothyroid membrane (CTM) - hypoechoic gap between thyroid and cricoid cartilages
  • Cricoid cartilage - echogenic ring inferior to CTM
  • Tracheal rings - hyperechoic anterior walls with posterior acoustic shadowing (the "snowstorm" artifact from air)
  • Trachea - anechoic lumen posterior to rings
  • Thyroid gland - bilateral, echogenic, flanks trachea
  • Oesophagus - posterior and lateral to trachea (best seen on left side)
  • Vocal cords - seen on coronal view through thyroid cartilage

PROBE SELECTION AND TECHNIQUE

ViewProbeFrequencyBest For
TransverseLinear7.5-15 MHzTrachea, CTM, ETT position
LongitudinalLinear7.5-15 MHzTracheal rings counting
Coronal (through thyroid)Linear7.5-15 MHzVocal cord movement
SubglotticLinear7.5-15 MHzETT size selection

APPLICATIONS IN AIRWAY ASSESSMENT

1. Prediction of Difficult Airway

  • Pre-tracheal soft tissue thickness: distance from skin to anterior tracheal wall > 28 mm in obese patients predicts difficult laryngoscopy
  • Tongue base thickness: hyoid-to-mental distance on submandibular scan correlates with Mallampati
  • Sublingual space: hyoid-to-floor-of-mouth distance; reduced in obese patients
  • Neck circumference: identified on US correlates with difficult mask ventilation
  • Anterior neck fat: quantifiable, relevant in morbidly obese patients

2. Identification of the Cricothyroid Membrane (CTM)

  • Critical application: palpation-based CTM identification fails in up to 65% of cases, particularly in obese/female patients
  • Ultrasound reliably identifies CTM by visualising the hypoechoic gap between thyroid and cricoid cartilages
  • USEFUL protocol (Ultrasound for the Systematic Identification of Landmarks for Emergency airway) uses systematic scanning from thyroid to cricoid
  • Pre-marking the CTM under ultrasound before anaesthesia induction is recommended in anticipated difficult airways (Miller's Anesthesia 10e)

3. Subglottic Diameter and ETT Size Selection

  • Transverse view of trachea at subglottic level measures the air-mucosa interface
  • ETT outer diameter should not exceed 80% of tracheal diameter
  • Particularly useful in paediatric patients where cuffed vs uncuffed tube selection affects mucosal injury
  • Reduces post-extubation stridor in children

APPLICATIONS IN AIRWAY MANAGEMENT

4. Confirmation of Endotracheal Tube Placement

Tracheal intubation:
  • Transverse view of neck shows single "double-tract sign" in trachea = correct placement
  • Movement of ETT tip visible in real-time as it passes through tracheal rings (Morgan & Mikhail 7e, Figure 19-7)
Oesophageal intubation detection:
  • Two "double-tract signs" seen - one in trachea, one in oesophagus (posterior-lateral)
  • Sensitivity of ultrasound for oesophageal intubation: 97-100% in studies
  • Faster than clinical auscultation in noisy environments
Dynamic view:
  • Real-time sliding motion of ETT within trachea during intubation visible on US screen
  • Tube passes as a hyperechoic area within the trachea

5. Confirmation of Bilateral Lung Ventilation

  • Lung sliding sign: pleural sliding (shimmering) seen bilaterally confirms bilateral ventilation
  • Absence of lung sliding on one side = endobronchial intubation or pneumothorax
  • M-mode: seashore sign (normal) vs barcode sign (no ventilation)
  • Highly sensitive (95%) for detecting endobronchial intubation

6. Diaphragm Assessment

  • Paradoxical or reduced diaphragm movement can identify phrenic nerve palsy
  • Helps assess adequacy of neuromuscular reversal before extubation

7. Ultrasound-Guided Percutaneous Tracheostomy

  • Real-time guidance for needle insertion between tracheal rings
  • Identifies pre-tracheal vessels (avoid puncture of thyroid vessels / innominate artery)
  • Reduces complications of percutaneous dilatational tracheostomy
  • Confirms intraluminal wire/airway cannula position (Miller's Anesthesia 10e)

8. Emergency Cricothyrotomy

  • In "can't intubate, can't oxygenate" scenarios
  • Pre-identification of CTM with ultrasound improves first-pass success
  • Real-time needle guidance for surgical airway

9. Evaluation of Airway Pathology

  • Tracheal deviation / compression from goitre, haematoma, lymphadenopathy
  • Subglottic stenosis (reduced air column diameter)
  • Tracheomalacia assessment

ADVANTAGES OF ULTRASOUND FOR AIRWAY

AdvantageClinical Relevance
Non-invasive, no radiationSafe in pregnancy, paediatrics, repeated use
Real-time dynamic imagingContinuous monitoring during procedures
Bedside availabilityEmergency department, ICU, operating room
Confirmation of ETT placementFaster than X-ray, comparable to capnography
Identifies CTM in obese patientsCrucial for surgical airway planning
Detects endobronchial intubationFaster than clinical signs

LIMITATIONS

  • Operator dependent - requires training and regular practice
  • Obesity and subcutaneous emphysema degrade image quality (air scatters ultrasound)
  • Dynamic intubation is challenging to capture in real-time
  • Cannot visualise larynx beyond vocal cords in non-sagittal views
  • Does not replace capnography as gold standard for ETT confirmation
  • Limited evidence for some applications (e.g., difficult airway prediction) compared to established clinical scoring systems

CONCLUSION

Ultrasound has transitioned from a supplementary tool to an integral component of modern airway management. Its greatest contribution is the real-time, bedside identification of the cricothyroid membrane and confirmation of tracheal vs oesophageal intubation, areas where traditional clinical methods are unreliable. With increasing POCUS training in anaesthesia curricula, ultrasound will continue to expand its role in routine and emergency airway management. (Morgan & Mikhail 7e; Miller's Anesthesia 10e)


QUESTION 4: Hospital Acquired Infections (HAI) - Definition, Causes, Prevention and Management of Ventilator Associated Pneumonia (VAP)


PART A: HOSPITAL ACQUIRED INFECTIONS (HAI)

Definition

A Hospital Acquired Infection (HAI), also called nosocomial infection, is an infection that:
  • Was not present or incubating at the time of hospital admission
  • Develops 48 hours or more after admission to a healthcare facility
  • May manifest up to 30 days after discharge (or 1 year for implant-related infections)
HAIs include: ventilator-associated pneumonia (VAP), catheter-associated urinary tract infections (CAUTI), central line-associated bloodstream infections (CLABSI), and surgical site infections (SSI).

Epidemiology

  • HAP and VAP account for approximately 28% of all HAIs and are the most frequent cause of nosocomial infection
  • Overall prevalence of nosocomial pneumonia: 0.89% of hospitalised patients
  • In ICU patients, VAP increases pneumonia incidence 20-fold
  • Approximately 10% of mechanically ventilated patients develop VAP (Fishman's Pulmonary Diseases 6e)

PART B: VENTILATOR ASSOCIATED PNEUMONIA (VAP)

Definition

VAP is pneumonia diagnosed 48 hours or more after endotracheal intubation, in a patient receiving mechanical ventilatory support.
Clinical Criteria (at least 2 of the following + new/progressive lung infiltrate):
  • Hyperthermia (fever > 38°C) or hypothermia (< 36°C)
  • Elevated white blood cell count (> 10,000/mm³)
  • Purulent tracheal secretions
  • Worsening oxygenation (rising FiO2 requirement or falling SpO2)
(Fishman's Pulmonary Diseases, Table 129-1)

CAUSES / PATHOPHYSIOLOGY

Primary mechanism: Aspiration of microorganisms colonising the aerodigestive tract into the lower respiratory tract in a host with impaired local and systemic immunity.
Why does colonisation increase in hospitalised patients?
  1. Pharmacologic/dietary alterations in gastric pH (stress ulcer prophylaxis with PPIs/H2 blockers)
  2. Exposure to contaminated respiratory equipment and hospital water systems
  3. Transmission of bacteria via healthcare workers (hands)
  4. Respiratory droplet spread of MDR organisms
  5. Disruption of normal oropharyngeal flora by broad-spectrum antibiotics
Risk Factors for VAP:
Patient-related:
  • Age > 60 years
  • Altered consciousness, ARDS
  • Chronic lung disease (COPD, bronchiectasis)
  • Immunosuppression
  • Prior antibiotic use within 90 days
  • Nasogastric tube (promotes reflux/aspiration)
Procedure-related:
  • Duration of mechanical ventilation (most important - risk increases up to day 5)
  • Reintubation
  • Supine positioning
  • Nasotracheal (vs. orotracheal) intubation
  • Indwelling vascular or urinary catheters
Microbiology of VAP (NHSN data, 2015-2017):
Pathogen% of IsolatesRank
Staphylococcus aureus (incl. MRSA)28.8%1st
Pseudomonas aeruginosa12.9%2nd
Klebsiella species10.1%3rd
Enterobacter species8.4%4th
Haemophilus influenzae5.9%5th
Escherichia coli5.6%7th
Acinetobacter species3.2%10th
Approximately 16.8% of isolates are multidrug-resistant (MDR) organisms.

PREVENTION OF VAP

Prevention is grouped into VAP bundles - simultaneous implementation of multiple measures produces greater impact than individual interventions.

The VAP Bundle (IHI - Institute for Healthcare Improvement)

Prevention StrategyEvidence Level
Semierect positioning (head of bed 30-45 degrees)Level 1
Oral decontamination with chlorhexidineLevel 1
Orotracheal (not nasotracheal) intubationLevel 1
Subglottic secretion drainage (suction port above cuff)Level 1
Use of polyurethane (vs PVC) endotracheal tube cuffLevel 1
Silver-coated endotracheal tubeLevel 1
Use of non-invasive ventilation (NIV) where possibleLevel 1
Rotational (kinetic) bedsLevel 1
Closed endotracheal suctioning systemLevel 1
Heat-moisture exchanger (HME)Level 1
Shortening duration of mechanical ventilation (daily SAT+SBT protocols)Level 1
Sedation vacations (SAT)Level 2
Adequate ICU nurse-to-patient staffingLevel 2
Avoid unnecessary reintubationLevel 2
Orogastric (not nasogastric) feeding tubeLevel 2
Restricted blood transfusionLevel 2
(Fishman's Pulmonary Diseases, Table 129-6)

NOT Recommended for VAP Prevention

  • Routine ventilator circuit changes
  • Chest physiotherapy
  • Early tracheostomy
  • Routine antibiotic cycling/rotation
  • Routine antibiotic prophylaxis (promotes MDR organisms)

MANAGEMENT OF VAP

Step 1: Assess Risk for MDR Organisms

High-risk features for MDR VAP:
  • Prior IV antibiotics in past 90 days
  • Hospitalisation > 5 days
  • Septic shock at VAP onset
  • ARDS prior to VAP
  • Acute renal replacement therapy
  • Residence in LTAC / skilled nursing facility

Step 2: Empirical Antibiotic Selection

Low risk for MDR (no risk factors):
  • One of: Piperacillin-tazobactam, Cefepime, Ceftriaxone, Levofloxacin, or Meropenem
  • No MRSA coverage needed if risk is low
High risk for MDR / MRSA:
  • Vancomycin OR Linezolid (MRSA coverage)
  • PLUS Anti-pseudomonal beta-lactam: Piperacillin-tazobactam, Cefepime, or Carbapenems
  • PLUS (if double gram-negative coverage needed): Aminoglycoside OR Ciprofloxacin
Key principle: Failure to initiate appropriate antibiotics promptly is an independent predictor of excess mortality. Change in initial empirical therapy was required in 43.7% of VAP cases in one large Spanish multicentre study.

Step 3: Duration of Therapy

  • 7-8 day course is as effective as longer courses for most VAP cases (evidence from IDSA/ATS 2016 guidelines)
  • Procalcitonin-guided de-escalation reduces antibiotic duration without worsening outcomes
  • Surveillance cultures and local antibiogram data should guide therapy

Step 4: De-escalation

  • After 48-72 hours, review cultures
  • Narrow antibiotics based on identified pathogen and sensitivities
  • Reduces emergence of MDR organisms
  • Reduces cost and adverse effects

Step 5: Non-Antibiotic Supportive Management

  • Optimise ventilator settings (lung-protective ventilation)
  • Continue VAP prevention bundle
  • Prone positioning if ARDS concurrent
  • Nutritional support

DIAGNOSIS OF VAP

Clinical criteria: CPIS score (Clinical Pulmonary Infection Score) - combines temperature, WBC, secretions, oxygenation, X-ray infiltrate, culture result (score > 6 suggests VAP)
Microbiological sampling:
  • Non-bronchoscopic BAL (mini-BAL)
  • Bronchoscopic BAL - gold standard
  • Protected specimen brushing
  • Endotracheal aspirate (sensitive but less specific)
Quantitative culture thresholds:
  • BAL: ≥ 10⁴ CFU/mL
  • Protected specimen brush: ≥ 10³ CFU/mL
  • Endotracheal aspirate: ≥ 10⁵-10⁶ CFU/mL

PROGNOSIS AND IMPACT

  • ICU mortality: 24.8%; In-hospital mortality: 31.9%
  • Attributable mortality: 1-27% (wide range due to confounding from severity of illness)
  • Mean additional hospital cost: $39,828 per patient
  • Attributable ICU length of stay: 4-13 days additional
  • VAP rate: 14.8 cases per 1000 ventilator days (Canadian multicentre study)

CONCLUSION

VAP is the most devastating and costly HAI in mechanically ventilated patients. Prevention through structured bundle protocols - particularly oral chlorhexidine, head-of-bed elevation, subglottic drainage, and minimising ventilator days - has Level 1 evidence and must be implemented universally. When VAP occurs, prompt initiation of appropriate empirical antibiotics (tailored to local resistance patterns), followed by early de-escalation guided by culture results, remains the cornerstone of treatment. (Fishman's Pulmonary Diseases 6e, Chapter 129; Barash Clinical Anesthesia 9e)


EXAM WRITING TIPS SPECIFIC TO ANAESTHESIA

  1. For "Role of X in present day practice" - always discuss: definition → rationale → how it's done → current evidence → limitations → conclusion. Use the word "Currently" or "In present day practice" in your intro.
  2. For "Recent Advances" - list advances under clear numbered headings. Each advance should have: name of advance + what it achieves + clinical relevance. Avoid listing historical background unless it sets context for the advance.
  3. For "Describe causes, prevention and management" - use a structured 3-part format. Causes under pathophysiology, prevention as a table/bundle, management as a step-by-step algorithm.
  4. Tables and boxes score marks in viva/practical assessment as they show organisation of knowledge.
  5. References in exam: mentioning "Miller's Anesthesia" or "IDSA 2016 guidelines" at the end of relevant points demonstrates reading beyond the basic textbook and impresses examiners.

Make a comprehensive study guide / summary DOCX on all 4 topics for quick revision

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || echo "workspace empty or missing"

Running Command

mkdir -p /tmp/workspace/anaesthesia-study-guide

Writing File

~/anaesthesia-study-guide/build_guide.py

from docx import Document
from docx.shared import Pt, Inches, RGBColor
from docx.enum.text import WD_ALIGN_PARAGRAPH
from docx.oxml.ns import qn
from docx.oxml import OxmlElement
import copy

doc = Document()

# ──────────────────────────────────────────────
# PAGE SETUP: A4, margins
# ──────────────────────────────────────────────
section = doc.sections[0]
section.page_width  = Inches(8.27)
section.page_height = Inches(11.69)
section.left_margin   = Inches(1.0)
section.right_margin  = Inches(1.0)
section.top_margin    = Inches(1.0)
section.bottom_margin = Inches(1.0)

# ──────────────────────────────────────────────
# COLOUR PALETTE
# ──────────────────────────────────────────────
DARK_BLUE    = RGBColor(0x1A, 0x35, 0x5E)   # deep navy
MED_BLUE     = RGBColor(0x2E, 0x6E, 0xBD)   # heading blue
ACCENT_TEAL  = RGBColor(0x00, 0x86, 0x96)   # teal subheadings
BOX_FILL     = RGBColor(0xE8, 0xF4, 0xFD)   # light blue box bg
WARN_FILL    = RGBColor(0xFF, 0xF3, 0xCD)   # amber for limitations
KEY_FILL     = RGBColor(0xD4, 0xED, 0xDA)   # green for key points
WHITE        = RGBColor(0xFF, 0xFF, 0xFF)
DARK_GRAY    = RGBColor(0x33, 0x33, 0x33)

# ──────────────────────────────────────────────
# BASE STYLE
# ──────────────────────────────────────────────
normal_style = doc.styles["Normal"]
normal_style.font.name = "Arial"
normal_style.font.size = Pt(10.5)
normal_style.font.color.rgb = DARK_GRAY

# ──────────────────────────────────────────────
# HELPER FUNCTIONS
# ──────────────────────────────────────────────

def set_cell_bg(cell, rgb: RGBColor):
    tc = cell._tc
    tcPr = tc.get_or_add_tcPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), f'{rgb[0]:02X}{rgb[1]:02X}{rgb[2]:02X}')
    tcPr.append(shd)

def set_cell_border(cell, **kwargs):
    """Add border to a cell. kwargs: top, bottom, left, right = 'single'"""
    tc = cell._tc
    tcPr = tc.get_or_add_tcPr()
    tcBorders = OxmlElement('w:tcBorders')
    for edge, val in kwargs.items():
        border = OxmlElement(f'w:{edge}')
        border.set(qn('w:val'), val)
        border.set(qn('w:sz'), '4')
        border.set(qn('w:space'), '0')
        border.set(qn('w:color'), '2E6EBD')
        tcBorders.append(border)
    tcPr.append(tcBorders)

def add_cover_title(doc, text):
    p = doc.add_paragraph()
    p.alignment = WD_ALIGN_PARAGRAPH.CENTER
    run = p.add_run(text)
    run.bold = True
    run.font.size = Pt(26)
    run.font.color.rgb = WHITE
    run.font.name = "Arial"
    # paragraph shading
    pPr = p._p.get_or_add_pPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), '1A355E')
    pPr.append(shd)
    p.paragraph_format.space_before = Pt(12)
    p.paragraph_format.space_after  = Pt(12)
    return p

def add_h1(doc, text):
    """Main topic heading - dark blue banner"""
    p = doc.add_paragraph()
    p.alignment = WD_ALIGN_PARAGRAPH.LEFT
    run = p.add_run(f"  {text}")
    run.bold = True
    run.font.size = Pt(15)
    run.font.color.rgb = WHITE
    run.font.name = "Arial"
    pPr = p._p.get_or_add_pPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), '1A355E')
    pPr.append(shd)
    p.paragraph_format.space_before = Pt(14)
    p.paragraph_format.space_after  = Pt(4)
    return p

def add_h2(doc, text):
    """Section heading - medium blue"""
    p = doc.add_paragraph()
    run = p.add_run(text)
    run.bold = True
    run.font.size = Pt(12.5)
    run.font.color.rgb = MED_BLUE
    run.font.name = "Arial"
    p.paragraph_format.space_before = Pt(10)
    p.paragraph_format.space_after  = Pt(2)
    # bottom border
    pPr = p._p.get_or_add_pPr()
    pBdr = OxmlElement('w:pBdr')
    bottom = OxmlElement('w:bottom')
    bottom.set(qn('w:val'), 'single')
    bottom.set(qn('w:sz'), '4')
    bottom.set(qn('w:space'), '1')
    bottom.set(qn('w:color'), '2E6EBD')
    pBdr.append(bottom)
    pPr.append(pBdr)
    return p

def add_h3(doc, text):
    """Sub-section heading - teal"""
    p = doc.add_paragraph()
    run = p.add_run(text)
    run.bold = True
    run.font.size = Pt(11)
    run.font.color.rgb = ACCENT_TEAL
    run.font.name = "Arial"
    p.paragraph_format.space_before = Pt(7)
    p.paragraph_format.space_after  = Pt(2)
    return p

def add_body(doc, text, indent=False):
    p = doc.add_paragraph()
    run = p.add_run(text)
    run.font.size = Pt(10.5)
    run.font.color.rgb = DARK_GRAY
    run.font.name = "Arial"
    if indent:
        p.paragraph_format.left_indent = Inches(0.25)
    p.paragraph_format.space_after = Pt(3)
    return p

def add_bullet(doc, text, level=0, bold_prefix=None):
    p = doc.add_paragraph(style='List Bullet')
    p.paragraph_format.left_indent  = Inches(0.25 + level * 0.25)
    p.paragraph_format.space_after  = Pt(2)
    if bold_prefix:
        r1 = p.add_run(bold_prefix + ": ")
        r1.bold = True
        r1.font.size = Pt(10.5)
        r1.font.name = "Arial"
        r1.font.color.rgb = DARK_GRAY
    r2 = p.add_run(text)
    r2.font.size = Pt(10.5)
    r2.font.name = "Arial"
    r2.font.color.rgb = DARK_GRAY
    return p

def add_box(doc, title, items, fill_rgb=None):
    """A shaded box with a title and bullet items."""
    if fill_rgb is None:
        fill_rgb = BOX_FILL
    tbl = doc.add_table(rows=1, cols=1)
    tbl.style = 'Table Grid'
    cell = tbl.rows[0].cells[0]
    set_cell_bg(cell, fill_rgb)
    # Title
    tp = cell.add_paragraph()
    tr = tp.add_run(title)
    tr.bold = True
    tr.font.size = Pt(11)
    tr.font.color.rgb = DARK_BLUE
    tr.font.name = "Arial"
    tp.paragraph_format.space_after = Pt(3)
    # Items
    for item in items:
        ip = cell.add_paragraph()
        ip.paragraph_format.left_indent = Inches(0.15)
        ir = ip.add_run(f"• {item}")
        ir.font.size = Pt(10)
        ir.font.name = "Arial"
        ir.font.color.rgb = DARK_GRAY
        ip.paragraph_format.space_after = Pt(1)
    # Remove first empty paragraph python-docx adds
    cell.paragraphs[0]._element.getparent().remove(cell.paragraphs[0]._element)
    p_after = doc.add_paragraph()
    p_after.paragraph_format.space_after = Pt(4)
    return tbl

def add_table(doc, headers, rows, header_fill=None):
    if header_fill is None:
        header_fill = MED_BLUE
    ncols = len(headers)
    tbl = doc.add_table(rows=1 + len(rows), cols=ncols)
    tbl.style = 'Table Grid'
    # Header row
    hdr_cells = tbl.rows[0].cells
    for i, h in enumerate(headers):
        set_cell_bg(hdr_cells[i], header_fill)
        p = hdr_cells[i].paragraphs[0]
        run = p.add_run(h)
        run.bold = True
        run.font.size = Pt(10)
        run.font.color.rgb = WHITE
        run.font.name = "Arial"
    # Data rows
    for ri, row_data in enumerate(rows):
        cells = tbl.rows[ri + 1].cells
        for ci, val in enumerate(row_data):
            # alternate shading
            if ri % 2 == 0:
                set_cell_bg(cells[ci], RGBColor(0xF5, 0xF9, 0xFF))
            p = cells[ci].paragraphs[0]
            run = p.add_run(str(val))
            run.font.size = Pt(10)
            run.font.name = "Arial"
            run.font.color.rgb = DARK_GRAY
    p_after = doc.add_paragraph()
    p_after.paragraph_format.space_after = Pt(6)
    return tbl

def add_spacer(doc, height_pt=6):
    p = doc.add_paragraph()
    p.paragraph_format.space_before = Pt(0)
    p.paragraph_format.space_after  = Pt(height_pt)

def add_divider(doc):
    p = doc.add_paragraph()
    pPr = p._p.get_or_add_pPr()
    pBdr = OxmlElement('w:pBdr')
    bottom = OxmlElement('w:bottom')
    bottom.set(qn('w:val'), 'single')
    bottom.set(qn('w:sz'), '6')
    bottom.set(qn('w:space'), '1')
    bottom.set(qn('w:color'), '1A355E')
    pBdr.append(bottom)
    pPr.append(pBdr)
    p.paragraph_format.space_before = Pt(4)
    p.paragraph_format.space_after  = Pt(4)

# ══════════════════════════════════════════════════════════
# COVER PAGE
# ══════════════════════════════════════════════════════════

add_cover_title(doc, "ANAESTHESIA QUICK REVISION GUIDE")

p = doc.add_paragraph()
p.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = p.add_run("Exam-Focused Study Notes | Jan 2025 & Sept 2025 Paper Topics")
r.font.size = Pt(12)
r.font.color.rgb = MED_BLUE
r.font.name = "Arial"
r.italic = True

add_spacer(doc, 8)

# Topic index box
add_box(doc, "TOPICS COVERED", [
    "1.  Opioid Free Anaesthesia (OFA) — Role, Benefits & Limitations",
    "2.  Recent Advances in Anaesthesia for Intrauterine Fetal Surgery",
    "3.  Ultrasound for Airway Assessment and Management",
    "4.  Hospital Acquired Infections & Ventilator Associated Pneumonia (VAP)",
], fill_rgb=RGBColor(0xE8, 0xF4, 0xFD))

add_spacer(doc, 8)

p2 = doc.add_paragraph()
p2.alignment = WD_ALIGN_PARAGRAPH.CENTER
r2 = p2.add_run("Sources: Miller's Anesthesia 10e | Morgan & Mikhail 7e | Barash Clinical Anesthesia 9e | Fishman's Pulmonary Diseases 6e")
r2.font.size = Pt(9)
r2.font.color.rgb = RGBColor(0x66, 0x66, 0x66)
r2.font.name = "Arial"
r2.italic = True

doc.add_page_break()

# ══════════════════════════════════════════════════════════
# TOPIC 1: OPIOID FREE ANAESTHESIA
# ══════════════════════════════════════════════════════════

add_h1(doc, "TOPIC 1: OPIOID FREE ANAESTHESIA (OFA)")

add_h2(doc, "Definition & Background")
add_body(doc, "Opioid Free Anaesthesia (OFA) is an anaesthetic technique in which opioids are completely avoided intraoperatively, relying on a combination of non-opioid analgesics, regional techniques, and adjuvant drugs to achieve analgesia and obtund the surgical stress response.")
add_spacer(doc, 4)
add_body(doc, "Opioid-Sparing Analgesia (OSA) = minimising (not eliminating) opioids. OFA is a subset of the broader OSA movement.")

add_h2(doc, "WHY OFA? — The Rationale")
add_box(doc, "Drivers of the OFA Movement", [
    "Global opioid epidemic — prescription opioid abuse crisis",
    "Opioid-induced hyperalgesia (OIH) — paradoxical pain sensitisation",
    "Postoperative nausea & vomiting (PONV) — opioids are the #1 cause",
    "Respiratory depression — especially in OSA, obese, elderly patients",
    "Postoperative delirium in ICU/elderly patients",
    "Immunosuppressive effects of opioids (NK cell suppression)",
    "Opioid tolerance and dependence risk in naive patients",
    "Delayed return of bowel function (opioid-induced ileus)",
], fill_rgb=BOX_FILL)

add_h2(doc, "Pharmacological Components of OFA")
add_table(doc,
    ["Drug Category", "Agents", "Mechanism"],
    [
        ["Alpha-2 agonists", "Dexmedetomidine, Clonidine", "Presynaptic alpha-2; reduces NE release; sedation + analgesia"],
        ["NMDA antagonists", "Ketamine (S-ketamine), Mg SO4", "Blocks NMDA receptor; prevents central sensitisation"],
        ["IV local anaesthetic", "Systemic Lidocaine infusion", "Na-channel block; anti-hyperalgesic; anti-inflammatory"],
        ["NSAIDs / COX-2i", "Ketorolac, Parecoxib, Celecoxib", "Inhibit prostaglandin synthesis peripherally"],
        ["Alpha-2-delta ligands", "Gabapentin, Pregabalin", "Block voltage-gated Ca2+ channels; reduce glutamate release"],
        ["Glucocorticoids", "Dexamethasone", "Anti-inflammatory; prolongs regional block duration"],
        ["Paracetamol", "IV/oral Acetaminophen", "Central & peripheral COX inhibition; supraspinal action"],
        ["Regional techniques", "Epidural, TAP, PEC blocks, PNBs", "Afferent blockade; prevent central sensitisation"],
        ["Beta-blockers", "Esmolol", "Blunts surgical stress haemodynamic response"],
        ["Volatile agents", "High-dose sevo/desflurane", "MAC-adjusted; provides immobility & some analgesia"],
    ]
)

add_h2(doc, "Benefits of OFA")
add_box(doc, "POTENTIAL BENEFITS", [
    "1. Reduces PONV — bariatric surgery studies show benefit beyond triple antiemetic prophylaxis",
    "2. Avoids respiratory depression — crucial in morbid obesity, OSA, paediatric tonsillectomy",
    "3. Prevents OIH — avoids paradoxical pain sensitisation from high-dose intraoperative opioids",
    "4. Reduces postoperative delirium — modifiable risk factor in elderly/ICU",
    "5. Faster return of bowel function — shorter ileus; supports ERAS protocols",
    "6. Shorter PACU stay and faster discharge",
    "7. Reduced chronic pain risk — less peripheral and central sensitisation",
    "8. Preserves immune function — avoids opioid-induced NK cell suppression",
    "9. No opioid dependence risk in naive patients",
], fill_rgb=KEY_FILL)

add_h2(doc, "Limitations of OFA")
add_box(doc, "LIMITATIONS / RISKS", [
    "1. Haemodynamic instability — large proof-of-concept RCT terminated early due to hypoxia & bradycardia",
    "2. Increased vasopressor requirement (dexmedetomidine causes bradycardia & hypotension)",
    "3. Postoperative sedation and falls (residual dexmedetomidine effect)",
    "4. Inadequate for highly nociceptive procedures without regional anaesthesia",
    "5. Dependence on regional techniques — block failure, haematoma, nerve injury risk",
    "6. Adjuvant drug side effects: Ketamine (dysphoria), NSAIDs (renal/GI), Pregabalin (dizziness)",
    "7. Limited high-quality RCT evidence for major cardiac/thoracic surgery",
    "8. Not universally superior — opioid-sparing approach may be more practical in most patients",
], fill_rgb=WARN_FILL)

add_h2(doc, "OFA vs Opioid-Sparing Analgesia")
add_table(doc,
    ["Feature", "OFA (Opioid Free)", "Opioid-Sparing (OSA)"],
    [
        ["Opioid dose", "Zero intraoperatively", "Reduced (not zero)"],
        ["Evidence base", "Limited RCTs", "Strong, well-established"],
        ["PONV benefit", "Maximum", "Significant"],
        ["Haemodynamic stability", "Potentially compromised", "Better"],
        ["Applicability", "Selected cases", "Near universal"],
        ["ERAS compatibility", "High", "High"],
        ["Typical candidates", "Bariatric, opioid-dependent, OSA", "All surgical patients"],
    ]
)

add_h2(doc, "Clinical Bottom Line")
add_box(doc, "KEY TAKE-HOME MESSAGE", [
    "OFA is NOT a universal solution — it is best reserved for selected patients",
    "Opioid-SPARING multimodal analgesia is the recommended standard for most patients",
    "A large proof-of-concept study was terminated early due to hypoxia and bradycardia (Miller's 10e)",
    "By using a multimodal pharmacological + regional approach, the anaesthesiologist can contribute to combating the opioid crisis while maintaining patient safety",
    "Pre-operative screening for chronic pain, opioid use, and substance abuse is essential",
], fill_rgb=BOX_FILL)

doc.add_page_break()

# ══════════════════════════════════════════════════════════
# TOPIC 2: INTRAUTERINE FETAL SURGERY
# ══════════════════════════════════════════════════════════

add_h1(doc, "TOPIC 2: ANAESTHESIA FOR INTRAUTERINE FETAL SURGERY")

add_h2(doc, "Introduction")
add_body(doc, "Fetal surgery encompasses in utero interventions to correct anatomical malformations causing irreversible harm if untreated. The anaesthesiologist faces a unique DUAL-PATIENT challenge: the pregnant mother AND the fetus. Success depends on multidisciplinary teamwork at a specialised fetal therapy centre. (Miller's Anesthesia 10e, Ch. 59)")

add_h2(doc, "Prerequisites for Fetal Surgery")
add_box(doc, "Criteria (must satisfy ALL)", [
    "Fetal lesion accurately diagnosed on imaging",
    "Progression & severity of anomaly predictable and well-understood",
    "No other severe anomalies contraindicating intervention",
    "Without treatment: fetal demise, irreversible organ damage, or severe neonatal morbidity",
    "Risk to the pregnant patient is acceptably low",
    "Animal model feasibility demonstrated",
    "Ethics committee approval; full informed consent obtained",
    "Specialised multidisciplinary centre (Level II or III)",
], fill_rgb=BOX_FILL)

add_h2(doc, "Classification of Fetal Surgery Procedures")
add_table(doc,
    ["Type", "Technique", "Anaesthesia Used"],
    [
        ["Minimally invasive (FIGS-IT)", "US-guided percutaneous needle procedures", "Local + IV sedation"],
        ["Fetoscopic surgery", "Small scope; percutaneous; US + camera guidance", "Local, sedation, or neuraxial (CSE/epidural)"],
        ["Open fetal surgery", "Maternal laparotomy + hysterotomy", "General anaesthesia (MANDATORY)"],
        ["EXIT procedure", "Delivery while placenta intact; airway secured", "General anaesthesia + epidural"],
    ]
)

add_h2(doc, "Conditions & RCT Evidence")
add_table(doc,
    ["Condition", "Procedure", "Trial / Evidence"],
    [
        ["Twin-to-Twin Transfusion Syndrome (TTTS)", "Fetoscopic laser photocoagulation of placental vessels", "Level I RCT — standard of care"],
        ["Myelomeningocele (spina bifida)", "Open or fetoscopic MMC repair", "MOMS Trial — improved motor function"],
        ["Congenital Diaphragmatic Hernia (CDH)", "Fetal Endoscopic Tracheal Occlusion (FETO)", "TOTAL Trial — survival benefit in severe CDH"],
        ["Lower Urinary Tract Obstruction (LUTO)", "Vesico-amniotic shunt", "PLUTO Trial"],
        ["Sacrococcygeal Teratoma (SCT)", "Debulking for high-output cardiac failure", "Case series; Level III centres"],
        ["CPAM / pulmonary lesions", "Thoraco-amniotic shunt", "Selected cases"],
    ]
)

add_h2(doc, "Anaesthetic Management — Overview")
add_h3(doc, "A. Maternal Anaesthesia")
add_box(doc, "For Open Fetal Surgery", [
    "General anaesthesia REQUIRED",
    "High-dose volatile agent: Desflurane/Sevoflurane at 1.5–2 MAC",
    "  -> Provides: maternal anaesthesia + uterine relaxation (tocolysis) + transplacental fetal anaesthesia",
    "Supplemental IV: propofol, remifentanil infusion",
    "Epidural catheter inserted pre-op for postoperative pain management",
    "Arterial line + large-bore IV + type & crossmatch (haemorrhage risk)",
], fill_rgb=BOX_FILL)
add_box(doc, "For Fetoscopic / Minimally Invasive Procedures", [
    "Neuraxial anaesthesia preferred (spinal or CSE)",
    "OR: local infiltration + IV sedation (fentanyl + midazolam)",
    "No need for uterine relaxation agents in most cases",
    "Less maternal physiological derangement",
], fill_rgb=KEY_FILL)

add_h3(doc, "B. Fetal Anaesthesia and Analgesia")
add_body(doc, "Fetal pain perception: nociceptive pathways present by 24–28 weeks gestation. Fetal hormonal & haemodynamic stress responses to noxious stimuli are well-documented — direct fetal opioid analgesia attenuates these responses.")
add_spacer(doc, 4)
add_table(doc,
    ["Route", "Drugs", "Indications"],
    [
        ["Transplacental (maternal IV/inhalational)", "Volatile agents, opioids, benzodiazepines", "All open fetal surgery"],
        ["Intramuscular (IM into fetus)", "Fentanyl 10–20 mcg/kg + Atropine 20 mcg/kg + Vecuronium", "Fetoscopic procedures"],
        ["Intra-umbilical vein injection", "Fentanyl, atropine, muscle relaxant", "When IM access difficult"],
    ]
)

add_h3(doc, "C. Uterine Relaxation (Tocolysis)")
add_box(doc, "Tocolytic Strategy", [
    "INTRAOPERATIVE: High-dose volatile agents (primary; dose-dependent uterine relaxation)",
    "INTRAOPERATIVE ADJUNCT: IV Nitroglycerin (rapid onset, short duration)",
    "PERIOPERATIVE: IV Magnesium sulphate",
    "POSTOPERATIVE: Nifedipine (Ca-channel blocker) or Indomethacin (PG inhibitor)",
    "Indometacin caution: avoid after 32 weeks (premature ductal closure)",
], fill_rgb=BOX_FILL)

add_h3(doc, "D. Fetal Monitoring")
add_box(doc, "Fetal Monitoring Methods", [
    "Continuous fetal echocardiography / fetal heart rate monitoring throughout procedure",
    "Umbilical artery Doppler — detects flow abnormalities (sign of fetal compromise)",
    "Fetal pulse oximetry (limited; used on exteriorised limb in open surgery)",
    "Fetal scalp electrode (when applicable)",
    "Immediate access to fetal resuscitation drugs: atropine, epinephrine",
], fill_rgb=BOX_FILL)

add_h2(doc, "Recent Advances (Exam High-Yield)")
add_table(doc,
    ["Advance", "Key Points"],
    [
        ["Fetoscopic MMC Repair", "3-port technique; CSE anaesthesia; reduced maternal morbidity vs open surgery"],
        ["FETO for CDH (TOTAL Trial)", "Balloon at 27–30 wks; removed at 34 wks; neuraxial/local anaesthesia; benefit in liver-up CDH with o/e LHR < 25%"],
        ["EXIT Procedure", "High-dose volatile; uterus kept relaxed; airway secured on placental bypass before cord cut"],
        ["Fetal Cardiac Interventions", "Aortic/pulmonary valvuloplasty; US-guided percutaneous; fetal IM injection; 60–70% technical success"],
        ["Neurodevelopmental Safety", "FDA 2016 warning re: anaesthetics & developing brain; GAS trial: single short exposure = minimal risk"],
        ["Three-Level Fetal Centres", "Level I: low risk; Level II: ICU capable; Level III: all open + all complications"],
        ["Bioethics & Counselling", "Termination, watchful waiting, or intervention — all must be offered; informed consent paramount"],
    ]
)

add_h2(doc, "Complications & Management")
add_table(doc,
    ["Complication", "Management"],
    [
        ["Fetal bradycardia", "Atropine IM/IV into fetus; adjust volatile conc; maternal ephedrine"],
        ["PPROM (most common)", "Most frequent complication; conservative or delivery based on GA"],
        ["Preterm labour", "Tocolysis: magnesium, nifedipine; monitor CTG 24–48 h post-op"],
        ["Maternal haemorrhage", "Blood products; uterotonics after fetus delivered"],
        ["Mirror syndrome", "Severe preeclampsia mimic; delivery usually required"],
        ["Fetal demise", "Emergency caesarean or expectant management based on GA"],
    ]
)

doc.add_page_break()

# ══════════════════════════════════════════════════════════
# TOPIC 3: ULTRASOUND FOR AIRWAY
# ══════════════════════════════════════════════════════════

add_h1(doc, "TOPIC 3: ULTRASOUND FOR AIRWAY ASSESSMENT & MANAGEMENT")

add_h2(doc, "Introduction")
add_body(doc, "Point-of-care ultrasound (POCUS) provides real-time, dynamic, objective anatomical information of the airway without radiation. It has transformed from a supplementary tool to an integral component of modern airway practice — for pre-operative planning, intubation guidance, ETT confirmation, and emergency airway rescue. (Morgan & Mikhail 7e; Miller's Anesthesia 10e)")

add_h2(doc, "Ultrasound Anatomy of the Airway")
add_table(doc,
    ["Structure", "US Appearance", "Clinical Relevance"],
    [
        ["Thyroid cartilage", "Echogenic; inverted V-shape anteriorly", "Landmark for CTM identification"],
        ["Cricothyroid membrane (CTM)", "Hypoechoic gap between thyroid & cricoid", "Surgical airway landmark"],
        ["Cricoid cartilage", "Echogenic ring; inferior to CTM", "Defines subglottic space"],
        ["Tracheal rings", "Hyperechoic anterior walls; posterior acoustic shadow", "Counting rings for tracheostomy level"],
        ["Trachea (lumen)", "Anechoic lumen behind rings; 'snowstorm' artifact from air", "Confirms tracheal vs oesophageal intubation"],
        ["Thyroid gland", "Bilateral echogenic; flanks trachea", "Avoidance during tracheostomy"],
        ["Oesophagus", "Posterior & lateral to trachea (usually left)", "Identifies oesophageal intubation"],
        ["Vocal cords", "Coronal view through thyroid cartilage; symmetrical hyperechoic bands", "Vocal cord mobility assessment"],
    ]
)

add_h2(doc, "Probe & Views")
add_table(doc,
    ["View", "Probe", "Frequency", "Best Used For"],
    [
        ["Transverse (cross-section)", "Linear", "7.5–15 MHz", "Trachea, CTM, oesophagus, ETT position"],
        ["Longitudinal (sagittal)", "Linear", "7.5–15 MHz", "Tracheal ring counting; tracheostomy planning"],
        ["Coronal (through thyroid cartilage)", "Linear", "7.5–15 MHz", "Vocal cord movement"],
        ["Subglottic transverse", "Linear", "7.5–15 MHz", "Tracheal diameter; ETT size selection"],
    ]
)

add_h2(doc, "Application 1: Pre-operative Airway Assessment")
add_box(doc, "Predicting Difficult Airway with Ultrasound", [
    "Pre-tracheal soft tissue thickness: >28 mm skin-to-trachea predicts difficult laryngoscopy (obese patients)",
    "Tongue base thickness: hyoid-to-mental distance correlates with Mallampati class",
    "Sublingual space (hyoid to floor of mouth): reduced in obesity — predicts difficult mask ventilation",
    "Anterior neck fat: quantifiable; relevant for bag-mask ventilation difficulty",
    "Neck circumference: identified on US; > 43 cm associated with difficult intubation",
], fill_rgb=BOX_FILL)

add_h2(doc, "Application 2: Cricothyroid Membrane (CTM) Identification")
add_box(doc, "Why Ultrasound CTM Identification Matters", [
    "Palpation-based CTM identification FAILS in up to 65% of cases — especially in obese & female patients",
    "Ultrasound reliably identifies CTM by the hypoechoic gap between thyroid and cricoid cartilages",
    "USEFUL Protocol: systematic scanning from thyroid notch to cricoid for CTM marking",
    "Pre-operative US marking of CTM recommended in anticipated difficult airways BEFORE induction",
    "Directly improves success rate of emergency cricothyrotomy in 'can't intubate, can't oxygenate' scenarios",
], fill_rgb=WARN_FILL)

add_h2(doc, "Application 3: ETT Placement Confirmation")
add_table(doc,
    ["Scenario", "US Finding", "Interpretation"],
    [
        ["Tracheal intubation", "Single 'double-tract sign' in trachea (hyperechoic lines)", "CORRECT — tracheal placement"],
        ["Oesophageal intubation", "Two 'double-tract signs': one in trachea + one in oesophagus (posterior-lateral)", "INCORRECT — pull back immediately"],
        ["Dynamic real-time view", "ETT tip visible passing through tracheal rings as hyperechoic area", "Real-time intubation confirmation"],
    ]
)
add_body(doc, "Sensitivity of ultrasound for detecting oesophageal intubation: 97–100%. Faster than clinical auscultation in noisy environments (ED, ICU).", indent=True)
add_body(doc, "Note: Capnography remains the GOLD STANDARD — ultrasound is a rapid adjunct, not a replacement.", indent=True)

add_h2(doc, "Application 4: Bilateral Lung Ventilation Confirmation")
add_box(doc, "Lung Ultrasound for Ventilation", [
    "Lung sliding sign (B-mode): pleural line shimmering bilaterally = bilateral ventilation confirmed",
    "Absent lung sliding on one side = endobronchial intubation or pneumothorax",
    "M-mode: SEASHORE SIGN = normal ventilation; BARCODE SIGN = no ventilation",
    "Sensitivity for endobronchial intubation: ~95%",
    "Diaphragm assessment: bilateral dome excursion confirms symmetric ventilation",
], fill_rgb=BOX_FILL)

add_h2(doc, "Application 5: ETT Size Selection (Subglottic Diameter)")
add_bullet(doc, "Transverse US view at subglottic level measures air-mucosa interface diameter")
add_bullet(doc, "ETT outer diameter should be ≤80% of tracheal internal diameter")
add_bullet(doc, "Especially useful in paediatric patients — reduces post-extubation stridor")
add_bullet(doc, "Reduces need for ETT exchange due to size mismatch")

add_h2(doc, "Application 6: Percutaneous Tracheostomy Guidance")
add_box(doc, "Ultrasound-Guided Percutaneous Tracheostomy", [
    "Identifies pre-tracheal vessels — avoids thyroid vessels and innominate artery puncture",
    "Confirms needle insertion between tracheal rings (not into thyroid or vessels)",
    "Real-time guidance for Seldinger wire placement",
    "Confirms intraluminal wire position before dilation",
    "Reduces pneumothorax, haemorrhage, and false passage complications",
], fill_rgb=BOX_FILL)

add_h2(doc, "Advantages vs Limitations")
add_table(doc,
    ["Advantages", "Limitations"],
    [
        ["Non-invasive, no radiation", "Operator dependent — needs training"],
        ["Real-time dynamic imaging", "Obesity/subcutaneous emphysema degrades image quality"],
        ["Bedside — OR, ICU, ED", "Cannot visualise larynx beyond vocal cords"],
        ["Detects oesophageal intubation (97–100%)", "Does NOT replace capnography (gold standard)"],
        ["CTM identification in obese patients", "Real-time intubation technically challenging"],
        ["Detects endobronchial intubation rapidly", "Limited evidence for difficult airway prediction vs clinical scoring"],
        ["No sedation or patient cooperation required", "Equipment cost and availability variable"],
    ]
)

add_h2(doc, "Summary Algorithm: Ultrasound in Airway Management")
add_box(doc, "STEP-BY-STEP APPROACH", [
    "PRE-OP: Assess anterior neck soft tissue; identify CTM; measure subglottic diameter",
    "  -> In obese/difficult airway: mark CTM under US before induction",
    "DURING INTUBATION: Real-time transverse neck view to confirm ETT in trachea",
    "POST-INTUBATION: Bilateral lung sliding to confirm bilateral ventilation",
    "IF DOUBT: Two-point scan (neck + lungs) takes < 30 seconds",
    "FOR TRACHEOSTOMY: Pre-procedural vessel mapping; real-time needle guidance",
    "EMERGENCY: Pre-marked CTM guides surgical airway in CICO scenario",
], fill_rgb=RGBColor(0xE8, 0xF4, 0xFD))

doc.add_page_break()

# ══════════════════════════════════════════════════════════
# TOPIC 4: HAI & VAP
# ══════════════════════════════════════════════════════════

add_h1(doc, "TOPIC 4: HOSPITAL ACQUIRED INFECTIONS & VENTILATOR ASSOCIATED PNEUMONIA")

add_h2(doc, "Hospital Acquired Infections (HAI) — Overview")
add_box(doc, "Definition of HAI (Nosocomial Infection)", [
    "Infection NOT present or incubating at time of hospital admission",
    "Develops 48 hours or more after admission",
    "May manifest up to 30 days post-discharge (or 1 year for implant-related infections)",
    "Types: VAP, CAUTI, CLABSI, SSI, C. difficile infection",
], fill_rgb=BOX_FILL)

add_table(doc,
    ["HAI Type", "Definition", "Common Organism"],
    [
        ["VAP", "Pneumonia ≥48 h after intubation", "S. aureus, Pseudomonas, Klebsiella"],
        ["HAP (non-ventilated)", "Pneumonia ≥48 h after admission (non-intubated)", "Same as VAP"],
        ["CAUTI", "UTI with urinary catheter in situ", "E. coli, Klebsiella, Candida"],
        ["CLABSI", "BSI with central venous catheter", "CoNS, S. aureus, Candida"],
        ["SSI", "Surgical site infection within 30 days", "S. aureus, E. coli, Enterococcus"],
    ]
)

add_h2(doc, "VENTILATOR ASSOCIATED PNEUMONIA (VAP)")

add_h3(doc, "Definition")
add_box(doc, "VAP — Clinical Definition", [
    "Pneumonia diagnosed 48 hours or more after endotracheal intubation",
    "Clinical criteria: New/progressive lung infiltrate PLUS 2 of the following:",
    "  1. Hyperthermia (>38°C) or hypothermia (<36°C)",
    "  2. WBC > 10,000/mm³ or leucopenia",
    "  3. Purulent tracheal secretions",
    "  4. Worsening oxygenation (rising FiO2 / falling SpO2)",
    "Early VAP: < 4 days — likely community-sensitive organisms",
    "Late VAP:  ≥ 5 days — higher risk of MDR organisms",
], fill_rgb=BOX_FILL)

add_h3(doc, "Epidemiology (High-Yield Numbers)")
add_box(doc, "Key Statistics to Memorise", [
    "VAP = most common HAI in ICU; accounts for 28% of ALL HAIs",
    "Mechanical ventilation increases pneumonia risk 20-FOLD",
    "~10% of mechanically ventilated patients develop VAP",
    "VAP rate: 14.8 cases per 1000 ventilator days (Canadian multicentre study)",
    "ICU mortality: 24.8%; In-hospital mortality: 31.9%",
    "Attributable ICU LOS increase: 4–13 days",
    "Additional hospitalisation cost: ~$39,828 per patient",
], fill_rgb=WARN_FILL)

add_h3(doc, "Pathophysiology / Causes")
add_body(doc, "Primary route: Aspiration of microorganisms colonising the oropharynx/aerodigestive tract into the lower respiratory tract in a host with impaired immunity.")
add_spacer(doc, 4)
add_box(doc, "Why Does Colonisation Increase in Hospitalised Patients?", [
    "Altered gastric pH from PPIs/H2-blockers (stress ulcer prophylaxis) -> gastric overgrowth",
    "Contaminated respiratory equipment and hospital water systems",
    "Healthcare worker hand transmission (most preventable route)",
    "Respiratory droplet spread of MDR organisms",
    "Disruption of normal oropharyngeal flora by broad-spectrum antibiotics",
    "Impaired host immunity: severity of illness, immunosuppression, malnutrition",
], fill_rgb=BOX_FILL)

add_h3(doc, "Microbiology (NHSN 2015–2017 Data)")
add_table(doc,
    ["Pathogen", "% Isolates", "Rank", "Key Note"],
    [
        ["Staphylococcus aureus (MRSA incl.)", "28.8%", "1st", "Most common; MRSA needs vancomycin/linezolid"],
        ["Pseudomonas aeruginosa", "12.9%", "2nd", "MDR common; anti-pseudomonal coverage needed"],
        ["Klebsiella species", "10.1%", "3rd", "ESBL possible; carbapenems if resistant"],
        ["Enterobacter species", "8.4%", "4th", "Inducible AmpC resistance"],
        ["Haemophilus influenzae", "5.9%", "5th", "Sensitive organisms; early VAP"],
        ["Escherichia coli", "5.6%", "7th", "ESBL strains increasing"],
        ["Acinetobacter species", "3.2%", "10th", "Highly MDR; outbreak risk in ICU"],
    ]
)
add_body(doc, "16.8% of all VAP isolates show resistance to ≥3 antibiotic classes (MDR).", indent=True)

add_h3(doc, "Risk Factors for VAP")
add_table(doc,
    ["Patient-Related Risk Factors", "Procedure/Environment-Related"],
    [
        ["Age > 60 years", "Duration of mechanical ventilation (most important)"],
        ["Altered consciousness / sedation", "Supine positioning (flat bed)"],
        ["Chronic lung disease (COPD, bronchiectasis)", "Nasotracheal intubation (vs orotracheal)"],
        ["ARDS prior to VAP", "Reintubation"],
        ["Immunosuppression / steroids", "Nasogastric tube (promotes aspiration)"],
        ["Prior IV antibiotics within 90 days", "Frequent ventilator circuit handling"],
        ["Septic shock at VAP onset", "Inadequate nurse-to-patient ratio"],
        ["Acute renal replacement therapy", "Indwelling vascular/urinary catheters"],
    ]
)

add_h2(doc, "PREVENTION OF VAP")

add_h3(doc, "VAP Prevention Bundle (IHI Ventilator Bundle)")
add_body(doc, "Bundle = simultaneous implementation of ALL measures (synergistic effect greater than individual interventions)")
add_table(doc,
    ["Prevention Strategy", "Evidence", "Notes"],
    [
        ["Semierect positioning (HOB 30–45°)", "Level 1 RCT", "Reduces micro-aspiration"],
        ["Oral chlorhexidine decontamination", "Level 1 RCT", "0.12% or 0.2% twice daily"],
        ["Orotracheal (not nasotracheal) intubation", "Level 1 RCT", "Nasotracheal promotes sinusitis + VAP"],
        ["Subglottic secretion drainage", "Level 1 RCT", "Special ETT with suction port above cuff"],
        ["Polyurethane ETT cuff (not PVC)", "Level 1 RCT", "Reduces micro-aspiration around cuff"],
        ["Silver-coated ETT", "Level 1 RCT", "Anti-biofilm; reduces early VAP"],
        ["Closed ETT suctioning system", "Level 1 RCT", "Prevents VAP from open suctioning"],
        ["Heat-moisture exchanger (HME)", "Level 1 RCT", "Replaces heated humidifier"],
        ["Rotational / kinetic beds", "Level 1 RCT", "Prevents secretion pooling"],
        ["Non-invasive ventilation (NIV) where possible", "Level 1 RCT", "Avoids intubation entirely"],
        ["Daily SAT + SBT protocol (minimise vent days)", "Level 1 RCT", "Every day on vent = VAP risk"],
        ["Daily sedation vacation (SAT)", "Level 2", "Allows neuro assessment; speeds extubation"],
        ["Avoid reintubation", "Level 2", "Each reintubation recontaminates airway"],
        ["Orogastric (not nasogastric) feeding tube", "Level 2", "Reduces sinusitis and aspiration"],
        ["Restricted blood transfusion", "Level 2", "Immunosuppressive effects of transfusion"],
    ]
)

add_box(doc, "NOT RECOMMENDED for VAP Prevention", [
    "Routine ventilator circuit changes (increases VAP risk by disturbing biofilm)",
    "Chest physiotherapy (no benefit for VAP prevention)",
    "Early tracheostomy (no VAP benefit; only improves patient comfort)",
    "Routine antibiotic cycling/rotation (promotes MDR selection)",
    "Routine antibiotic prophylaxis (causes MDR organisms)",
    "Specific stress ulcer prophylaxis regimen over another",
], fill_rgb=WARN_FILL)

add_h2(doc, "MANAGEMENT OF VAP")

add_h3(doc, "Step 1: Diagnosis")
add_box(doc, "CPIS Score (Clinical Pulmonary Infection Score) — Score > 6 suggests VAP", [
    "Temperature: 36.5–38.4°C = 0; 38.5–38.9°C = 1; ≥39 or ≤36 = 2",
    "WBC: 4000–11000 = 0; <4000 or >11000 = 1; + band forms >50% = +1",
    "Tracheal secretions: none = 0; non-purulent = 1; purulent = 2",
    "Oxygenation (PaO2/FiO2): >240 or ARDS = 0; ≤240 and no ARDS = 2",
    "Chest X-ray: no infiltrate = 0; diffuse = 1; localised = 2",
    "Culture of tracheal aspirate: negative = 0; positive = 1 or 2",
], fill_rgb=BOX_FILL)

add_h3(doc, "Microbiological Sampling (Quantitative Culture Thresholds)")
add_table(doc,
    ["Method", "CFU Threshold", "Notes"],
    [
        ["Bronchoscopic BAL", "≥10⁴ CFU/mL", "Gold standard; highest specificity"],
        ["Protected Specimen Brush (PSB)", "≥10³ CFU/mL", "Bronchoscopic; reduces contamination"],
        ["Non-bronchoscopic (mini) BAL", "≥10⁴ CFU/mL", "Bedside; no bronchoscopy needed"],
        ["Endotracheal aspirate", "≥10⁵–10⁶ CFU/mL", "Most available; lower specificity"],
    ]
)

add_h3(doc, "Step 2: Empirical Antibiotic Selection")
add_body(doc, "FIRST: Assess risk for MDR organisms", indent=False)
add_spacer(doc,3)
add_box(doc, "Risk Factors for MDR VAP", [
    "Prior IV antibiotics within 90 days",
    "Hospitalisation ≥ 5 days at time of VAP",
    "Septic shock at VAP onset",
    "ARDS prior to VAP onset",
    "Acute renal replacement therapy",
    "Residence in LTAC / skilled nursing facility",
], fill_rgb=WARN_FILL)
add_spacer(doc,4)
add_table(doc,
    ["Risk Category", "Antibiotic Regimen"],
    [
        ["Low MDR risk (early VAP, no risk factors)", "Monotherapy: Piperacillin-tazobactam OR Cefepime OR Levofloxacin OR Meropenem"],
        ["High MDR risk (late VAP / risk factors present)", "MRSA coverage: Vancomycin OR Linezolid\nPLUS Anti-pseudomonal beta-lactam: Pip-tazo / Cefepime / Carbapenem\nPLUS (if double GN needed): Aminoglycoside OR Ciprofloxacin"],
        ["MRSA-confirmed or high local prevalence", "Vancomycin (trough 15–20 mg/L) OR Linezolid 600 mg BD"],
    ]
)
add_body(doc, "KEY: Failure to initiate APPROPRIATE antibiotics promptly = independent predictor of mortality. Regimen change needed in 43.7% of VAP cases in one large Spanish multicentre study.", indent=True)

add_h3(doc, "Step 3: Duration & De-escalation")
add_box(doc, "Antibiotic Duration Principles", [
    "7–8 day course is as effective as 14–21 days for most VAP (IDSA/ATS 2016)",
    "Procalcitonin-guided de-escalation reduces antibiotic duration without worsening outcomes",
    "After 48–72 h: review cultures; NARROW to targeted therapy",
    "De-escalation reduces MDR emergence, costs, and adverse effects",
    "Prolonged therapy only for: Pseudomonas, Acinetobacter, non-fermenting GNB (10–14 days)",
], fill_rgb=KEY_FILL)

add_h3(doc, "Step 4: Supportive Management")
add_bullet(doc, "Lung-protective ventilation: TV 6 mL/kg IBW; plateau pressure < 30 cmH2O")
add_bullet(doc, "Prone positioning if concurrent ARDS (> 12 h/day)")
add_bullet(doc, "Continue VAP prevention bundle measures throughout ICU stay")
add_bullet(doc, "Nutritional support: enteral feeding preferred; avoid parenteral")
add_bullet(doc, "Glycaemic control: target 140–180 mg/dL (avoid hypoglycaemia)")
add_bullet(doc, "DVT prophylaxis: LMWH or UFH; compression stockings")

add_h2(doc, "Quick Summary: VAP at a Glance")
add_table(doc,
    ["Parameter", "Value / Key Point"],
    [
        ["Definition", "Pneumonia ≥48 h after intubation"],
        ["Most common pathogen", "Staphylococcus aureus (28.8%)"],
        ["Incidence", "~10% of ventilated patients; 14.8/1000 vent-days"],
        ["Most important risk factor", "Duration of mechanical ventilation"],
        ["Most important prevention", "Minimise ventilator days (daily SBT + SAT)"],
        ["Best diagnostic sample", "Bronchoscopic BAL (≥10⁴ CFU/mL)"],
        ["Antibiotic duration", "7–8 days (most cases)"],
        ["Attributable mortality", "1–27% (wide range; confounded by severity)"],
        ["Additional cost per case", "~$39,828 USD"],
        ["IDSA/ATS Guideline Year", "2016 (most recent major guideline)"],
    ]
)

add_spacer(doc, 12)
add_divider(doc)

# Footer note
p_footer = doc.add_paragraph()
p_footer.alignment = WD_ALIGN_PARAGRAPH.CENTER
r_footer = p_footer.add_run("Sources: Miller's Anesthesia 10e | Morgan & Mikhail's Clinical Anesthesiology 7e | Barash Clinical Anesthesia 9e | Fishman's Pulmonary Diseases & Disorders 6e | IDSA/ATS VAP Guidelines 2016")
r_footer.font.size = Pt(8.5)
r_footer.font.color.rgb = RGBColor(0x88, 0x88, 0x88)
r_footer.font.name = "Arial"
r_footer.italic = True

# ──────────────────────────────────────────────
# SAVE
# ──────────────────────────────────────────────
out_path = "/tmp/workspace/anaesthesia-study-guide/Anaesthesia_Quick_Revision_Guide.docx"
doc.save(out_path)
print(f"Saved: {out_path}")
Running Command

cd /tmp/workspace/anaesthesia-study-guide && python3 build_guide.py

Running Command

python3 -c " from docx import Document doc = Document('/tmp/workspace/anaesthesia-study-guide/Anaesthesia_Quick_Revision_Guide.docx') paras = [p.text.strip() for p in doc.paragraphs if p.text.strip()] print(f'Total paragraphs: {len(paras)}') print(f'Total tables: {len(doc.tables)}') # Print first 30 non-empty para texts for p in paras[:30]: print(' -', p[:80]) "

The document built successfully with 75 paragraphs and 41 tables. Here's your file:

Anaesthesia Quick Revision Guide

Word Document · DOCX


Here's what's inside:
Structure of the document:
SectionContent
Cover PageTitle banner + topic index + source credits
Topic 1 — OFADefinition, rationale, drug table, benefits box (green), limitations box (amber), OFA vs OSA comparison table, key take-home box
Topic 2 — Fetal SurgeryPrerequisites box, classification table, conditions + RCT evidence table, anaesthetic management (maternal/fetal/tocolysis/monitoring), recent advances table, complications table
Topic 3 — Airway UltrasoundAnatomy table, probe/views table, 6 clinical applications with boxes and tables, advantages vs limitations table, step-by-step algorithm box
Topic 4 — HAI & VAPHAI overview table, VAP definition box, key statistics box (amber), pathophysiology, microbiology table (NHSN data), risk factors table, full prevention bundle table with evidence levels, NOT recommended box, CPIS score box, culture thresholds table, empirical antibiotic table, MDR risk factors, duration/de-escalation box, quick summary table
Formatting highlights:
  • Deep navy heading banners for each topic
  • Blue underlined section headings
  • Teal sub-headings
  • Green boxes = key clinical points
  • Amber boxes = warnings / limitations
  • Light blue boxes = general information
  • All tables have colour-coded headers and alternating row shading
  • A4 page layout ready to print or share
This is a shared conversation. Sign in to Orris to start your own chat.